Ignite Creation Date:
2025-12-25 @ 5:01 AM
Ignite Modification Date:
2026-01-04 @ 8:50 AM
Study NCT ID:
NCT05069818
Status:
UNKNOWN
Last Update Posted:
2021-10-06
First Post:
2021-09-25
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Variance of HRD From Paired Ovarian Cancer
Sponsor:
Xiaoxiang Chen
Organization:
Study Overview
Official Title:
Variance of HRD From Primary to Recurrent in High-grade Serous Ovarian Cancer
Status:
UNKNOWN
Status Verified Date:
2021-09
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
HOPEII
Brief Summary:
Homologous recombination deficiency (HRD) is an important biomarker of poly (ADP-ribose) polymerase inhibitor (PARPi) in patients with high-grade serous ovarian cancer (HGSOC). The stability of HRD in the recurrent HGSOC and its primary pair remains unknown.
Detailed Description:
This study intends to perform HRD testing of ovarian cancer in the recurrent HGSOC and its primary pair, furtherly correlate HRD status and clinical characteristics in the recurited population.
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: